Location:
1102 Palo Verde Rd ,
Irvine, California 92617,
United States
Founded in: 2008 Stage: Alpha (prototype) Number of employees: 1-5 Completed funding: Government grant Profitable year: 2010 Short URL:http://vator.tv/c/f6c
Profile creation: April 24, 2009 Last updated: April 27, 2009
Categories
Biotech/Life Sciences, Business to Business, Health and Medical
Diamond coatings remain the optimal choice for strength and sharpness for precision surgical instruments; however their high costs prevent wide adoption in the healthcare industry today. DIAMAS’ innovative diamond nano-composite technology provides the solution, offering the strength of diamond with ultra- fine features at a fraction of the cost. DIAMAS offers an unprecedented value proposition with strong intellectual property placing it among the top contestants in the competitive landscape. DIAMAS targets a total market size of $4.57B in the United States by partnering with top surgical instrument manufacturers. DIAMAS will operate through off-site and in-factory coating services for licensing and operational fees. Financial projections estimate a revenue generation of $1.8 M by end of first year expected to rise to $10M by year 5 with a total startup cost of $750K. DIAMAS will achieve this goal through a management team with year of technological expertise, medical exposure and business experience
DIAMAS' direct customers are surgical instrument distributers/manufacturers that provide hospitals and specialty clinics with various tools for surgeries.DIAMAS will work towards strategic alliances with the major distributors to target addressable segments of the surgical instrumentation market. DIAMAS will start operations with mainstream revenues coming from coating fees including: coating costs, royalties and premiums.This will gradually transition into partnerships requiring coating services at customers’ facilities bringing revenues from lease, operations and maintenance of coating equipment.
DIAMAS offers diamond film coating services based on a patent-pending Diamond-like Nanocomposite (DLN) technology.Specifically, we envision this technology applied to specialty surgical instruments.DIAMAS films are unique because they can provide the sharpest cutting edges on the market with diamond-like hardness and atomic scale surface smoothness. DIAMAS is favourably positioned in the technology landscape offering most value for reasonable prices. DIAMAS' value proposition is the sharpest cutting technology at most affordable prices and hold a vision towards creating the highest standards without the highest prices
Mr.Gobind Bisht is the acting CEO and brings management and business experience along with knowledge of intellectual property protection. He holds a Technology Degree in Biotechnology from Indian Institute of Technology, Kharagour and currently MS candidate at UC Irvine.He has extensive business and technological experience as a founding researcher of DLN technology and a serial entrepreneur. He has been the founding member and business advisor to key events organized by IIT.
Mr.Robert Gorkin is the acting VP R&D and brings research experience from pharma gaint Merck & Co. and BioMEMS lab at UC Irvine. He holds a technology degree from University of Pittsburgh in Biomedical Engineering and currently a PhD candidate at UC Irvine. He expertises in consulting for technology startups while working with SubQ (Glucose sensing), Phasiks (On-chip diagnostics) and GenePOC (Sample-to-answer influenza detection).
DIAMAS is Patent Pending. The patentable IP includes the novel compositions of the DLN films, their synthesis methods and their material properties. Indian Patent on Core Technology has already been approved being followed by a PCT application to seek IP protection across US and globally.DIAMAS' innovation management strategy is to work towards creating a strong patent portfolio around its core technology.Typically, giant corporate houses surround improperly protected innovation with a series of close patents making it difficult for smaller players to expand.DIAMAS will avoid this situation by IP bulletproofing through several multiple patents covering the whole innovation landscape around the core technology.This will also help improve DIAMAS’ future valuation and negotiate better licensing profits.
I don't like the name. It sounds like "Die" a "mass", such as masses of people would die when using this technology. I would come up with a more friendly name.
They famously asked Willie Loman why he robbed banks ["that's where the money is!"]. Applying coating technology that differentiates a device adds value through improved performance. Your best margin play is in garnering the value for both coating and instrument. We have run several virtual companies, some through 510(k) approvals. You do not need brick and mortar, only nerves of steel to be an entrepreneur.
Thanks a lot for the feedback Stanton. Our present strategy is to partner with manufacturers who expertise in the FDA approval and have exisiting distribution channels. That way we dont spend too much money on brick and mortar and penetrate the market more effectively. Although profits are shared by our partners, we still make money doing what we do the best, coat instruments. Please feel free to reflect more on this. Appreciate your suggestions.
California,
United States
Finalist in 2009 Business Plan Competition at The Paul Merage School of Business
Follow DIAMAS on Vator.tv
Marc Madou